Recursion Pharmaceuticals, Inc.RXRXNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +158.19% | -57.54% | +9.30% | +32.62% | -80.16% |
| Gross Profit Growth | +0.00% | -1214.80% | -404.69% | -120.33% | -274.38% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +31.85% | +44.12% | +70.65% | +72.32% | +58.18% |
| Weighted Average Shares Diluted Growth | +31.85% | +44.12% | +70.65% | +72.32% | +58.18% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -28.73% | +1489.08% | +1674.68% | +755.34% | +871.62% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +15.17% | +121.60% | +133.98% | +67.86% | +92.64% |
| Book Value per Share Growth | -9.16% | +54.93% | +36.43% | -8.74% | +26.18% |
| Debt Growth | +76.05% | +114.11% | +82.27% | -2.00% | -9.10% |
| R&D Expense Growth | +6.56% | +41.52% | +91.88% | +74.00% | +62.28% |
| SG&A Expenses Growth | +29.31% | +153.42% | +74.00% | +46.56% | +10.25% |